Investor Relations

Company Information

MiNK Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class invariant natural killer T (iNKT) cell therapies to transform the lives of patients with cancer.
Press Releases
Aug 31, 2022
NEW YORK , Aug. 31, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated
Aug 02, 2022
NEW YORK , Aug. 02, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

SEC Filings

Form Description Filing date View
4

Statement of changes in beneficial ownership of securities

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML

Data provided by Kaleidoscope.

Events and Presentations
Corporate Presentation